Objective: Late dumping syndrome is a common postgastrectomy complication characterized by reactive hypoglycemia. This study aimed to explore the glycemic trend in patients who underwent gastrectomy for gastric cancer and clarify its changes over time in association with postgastrectomy symptoms.
Summary Background Data: Changes over time in glycemic trend in association with postgastrectomy symptoms have not been evaluated.
Methods: We conducted a prospective study of 71 patients who underwent curative gastrectomy for gastric cancer between November 2017 and April 2020. The patients underwent continuous glucose monitoring twice-at 1- and 12-month postgastrectomy-and were assessed using the Post-Gastrectomy Syndrome Assessment Scale 37-item questionnaire (PGSAS-37) at 1-, 6-, and 12-month postgastrectomy.
Results: Our results revealed that hypoglycemia (<70 mg/dL), especially nocturnal hypoglycemia (00:00-06:00), frequently occurred even at 12-month postgastrectomy. Hypoglycemia improved in total gastrectomy patients but remained unchanged in distal gastrectomy patients, which was still high in both groups at 12-month postgastrectomy. Glycemic variability (SD of the glycemic trend) was exacerbated in both gastrectomy groups. However, the PGSAS-37 symptom scores remained unchanged, and the living status and quality of life tended to improve. Hypoglycemia unawareness, including postprandial hypoglycemia without symptoms and nocturnal hypoglycemia, was evident even 12-month postgastrectomy.
Conclusions: Persistent postgastrectomy hypoglycemia unawareness, including late dumping syndrome without symptoms and nocturnal hypoglycemia, should be recognized as an important issue in postgastrectomy syndrome. Therefore, meticulous long-term evaluation for glycemic trends and care of patients is required.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431341 | PMC |
http://dx.doi.org/10.1097/AS9.0000000000000135 | DOI Listing |
J Biochem Mol Toxicol
February 2025
Department of Anorectal Center, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Circular RNA (CircRNA)s, a newly discovered type of noncoding RNAs, have been found to play a role in controlling the development and aggressiveness of tumors. Abnormal control of circRNA has been observed in various types of human cancers, including bladder cancer, hepatocellular carcinoma (HCC), breast cancer, and gastric cancer (GC). CircRNAs possess binding sites for microRNAs (miRNAs) and function as miRNA sponges in posttranscriptional regulation.
View Article and Find Full Text PDFDig Endosc
January 2025
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Clin Pharmacol Ther
January 2025
Gilead Sciences, Inc., Foster City, California, USA.
Obeldesivir is an oral nucleoside analog prodrug inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase and other viral polymerases. Here, two Phase I studies evaluated potential drug-drug interactions between obeldesivir and substrates or inhibitors of cytochrome P450 and drug transporters in healthy participants. When obeldesivir was tested as a precipitant, pharmacokinetic parameter point estimates for midazolam (CYP3A4 inhibition/induction), caffeine (CYP1A2 inhibition), and metformin (organic cation transporter 1 inhibition) exposures were within 80-125% no-effect bounds representing the interval within which a systemic exposure change does not warrant clinical action based on EMA/FDA guidance.
View Article and Find Full Text PDFmSphere
January 2025
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
is a major causative agent in several upper gastroduodenal tract diseases, including gastric cancer. The development of methods to genetically manipulate by natural transformation has allowed a greater understanding of its biology and role in these diseases. Nevertheless, the transformation methods used for are time-consuming, requiring growth of these fastidious and slow-growing bacteria from -80°C stocks.
View Article and Find Full Text PDFJ Asian Nat Prod Res
January 2025
Department of Pharmaceutical Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China.
The 3-O-(4'-imidazole)-12-en-olean-28-amide derivatives to through modification the C-3 and C-28 of the natural product oleanolic acid were prepared, and their structures were confirmed by MS,H NMR and C NMR. The antitumor activities of these compounds against breast cancer MCF-7 and gastric cancer SGC7901 cells were determined by MTT assay. Cell tests showed that the antitumor activities of compound exhibited significant antitumor activity which was equivalent to the positive control drug nilotinib, and the affinity was verified by molecular dynamics experiment .
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!